175 related articles for article (PubMed ID: 23778974)
1. Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway.
Arnesen T; Glomnes N; Strømsøy S; Knappskog S; Heie A; Akslen LA; Grytaas M; Varhaug JE; Gimm O; Brauckhoff M
Langenbecks Arch Surg; 2013 Aug; 398(6):869-74. PubMed ID: 23778974
[TBL] [Abstract][Full Text] [Related]
2. Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism.
Ip JC; Pang TC; Pon CK; Zhao JT; Sywak MS; Gill AJ; Soon PS; Sidhu SB
ANZ J Surg; 2015 Apr; 85(4):279-83. PubMed ID: 24274318
[TBL] [Abstract][Full Text] [Related]
3. KCNJ5 Somatic Mutation Is a Predictor of Hypertension Remission After Adrenalectomy for Unilateral Primary Aldosteronism.
Vilela LAP; Rassi-Cruz M; Guimaraes AG; Moises CCS; Freitas TC; Alencar NP; Petenuci J; Goldbaum TS; Maciel AAW; Pereira MAA; Silva GV; Pio-Abreu A; Zerbini MCN; Cavalcante ACBS; Carnevale FC; Pilan B; Yamauchi F; Srougi V; Tanno FY; Chambo JL; Latronico AC; Mendonca BB; Fragoso MCBV; Bortolotto LA; Drager LF; Almeida MQ
J Clin Endocrinol Metab; 2019 Oct; 104(10):4695-4702. PubMed ID: 31216002
[TBL] [Abstract][Full Text] [Related]
4. a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.
Monticone S; Hattangady NG; Penton D; Isales CM; Edwards MA; Williams TA; Sterner C; Warth R; Mulatero P; Rainey WE
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1861-5. PubMed ID: 24037882
[TBL] [Abstract][Full Text] [Related]
5. Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth.
Yang Y; Gomez-Sanchez CE; Jaquin D; Aristizabal Prada ET; Meyer LS; Knösel T; Schneider H; Beuschlein F; Reincke M; Williams TA
Hypertension; 2019 Oct; 74(4):809-816. PubMed ID: 31446799
[TBL] [Abstract][Full Text] [Related]
6. Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia.
Maria AG; Suzuki M; Berthon A; Kamilaris C; Demidowich A; Lack J; Zilbermint M; Hannah-Shmouni F; Faucz FR; Stratakis CA
Am J Hypertens; 2020 Feb; 33(2):124-130. PubMed ID: 31637427
[TBL] [Abstract][Full Text] [Related]
7. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas.
Taguchi R; Yamada M; Nakajima Y; Satoh T; Hashimoto K; Shibusawa N; Ozawa A; Okada S; Rokutanda N; Takata D; Koibuchi Y; Horiguchi J; Oyama T; Takeyoshi I; Mori M
J Clin Endocrinol Metab; 2012 Apr; 97(4):1311-9. PubMed ID: 22278422
[TBL] [Abstract][Full Text] [Related]
8. NP-59 Adrenal Scintigraphy as an Imaging Biomarker to Predict
Lu CC; Yen RF; Peng KY; Huang JY; Wu KD; Chueh JS; Lin WY
Front Endocrinol (Lausanne); 2021; 12():644927. PubMed ID: 33995277
[TBL] [Abstract][Full Text] [Related]
9. Adrenalectomy Completely Cured Hypertension in Patients With Familial Hyperaldosteronism Type I Who Had Somatic KCNJ5 Mutation.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chueh JS; Wu KD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5462-5466. PubMed ID: 31287546
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas.
Kitamoto T; Suematsu S; Matsuzawa Y; Saito J; Omura M; Nishikawa T
J Atheroscler Thromb; 2015; 22(2):191-200. PubMed ID: 25253161
[TBL] [Abstract][Full Text] [Related]
11. Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients.
Oßwald A; Fischer E; Degenhart C; Quinkler M; Bidlingmaier M; Pallauf A; Lang K; Mussack T; Hallfeldt K; Beuschlein F; Reincke M
Eur J Endocrinol; 2013 Nov; 169(5):657-63. PubMed ID: 23946277
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a mutated KCNJ5 gene, G387R, in unilateral primary aldosteronism.
Chueh JS; Peng KY; Wu VC; Wang SM; Chan CK; Chen YM; Ke YY; Pan CY; Liao HW
J Mol Endocrinol; 2021 Sep; 67(4):203-215. PubMed ID: 34463641
[TBL] [Abstract][Full Text] [Related]
13. Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism.
Maiolino G; Ceolotto G; Battistel M; Barbiero G; Cesari M; Amar L; Caroccia B; Padrini R; Azizi M; Rossi GP
Blood Press; 2018 Aug; 27(4):200-205. PubMed ID: 29409357
[TBL] [Abstract][Full Text] [Related]
14. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors.
Azizan EA; Lam BY; Newhouse SJ; Zhou J; Kuc RE; Clarke J; Happerfield L; Marker A; Hoffman GJ; Brown MJ
J Clin Endocrinol Metab; 2012 May; 97(5):E819-29. PubMed ID: 22442279
[TBL] [Abstract][Full Text] [Related]
15. KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism.
Rossi GP; Cesari M; Letizia C; Seccia TM; Cicala MV; Zinnamosca L; Kuppusamy M; Mareso S; Sciomer S; Iacobone M; Mantero F; Pessina AC
J Hypertens; 2014 Jul; 32(7):1514-21; discussion 1522. PubMed ID: 24759126
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism.
Boulkroun S; Beuschlein F; Rossi GP; Golib-Dzib JF; Fischer E; Amar L; Mulatero P; Samson-Couterie B; Hahner S; Quinkler M; Fallo F; Letizia C; Allolio B; Ceolotto G; Cicala MV; Lang K; Lefebvre H; Lenzini L; Maniero C; Monticone S; Perrocheau M; Pilon C; Plouin PF; Rayes N; Seccia TM; Veglio F; Williams TA; Zinnamosca L; Mantero F; Benecke A; Jeunemaitre X; Reincke M; Zennaro MC
Hypertension; 2012 Mar; 59(3):592-8. PubMed ID: 22275527
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and metabolic characters of
Chang YY; Lee BC; Chen ZW; Tsai CH; Chang CC; Liao CW; Pan CT; Peng KY; Chou CH; Lu CC; Wu VC; Hung CS; Lin YH;
Front Endocrinol (Lausanne); 2023; 14():1061704. PubMed ID: 36950676
[TBL] [Abstract][Full Text] [Related]
18. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism.
Murthy M; Xu S; Massimo G; Wolley M; Gordon RD; Stowasser M; O'Shaughnessy KM
Hypertension; 2014 Apr; 63(4):783-9. PubMed ID: 24420545
[TBL] [Abstract][Full Text] [Related]
19. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome.
Xekouki P; Hatch MM; Lin L; Rodrigo de A; Azevedo M; de la Luz Sierra M; Levy I; Saloustros E; Moraitis A; Horvath A; Kebebew E; Hoffman DA; Stratakis CA
Endocr Relat Cancer; 2012 Jun; 19(3):255-60. PubMed ID: 22323562
[TBL] [Abstract][Full Text] [Related]
20. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma.
Kitamoto T; Omura M; Suematsu S; Saito J; Nishikawa T
J Hypertens; 2018 Mar; 36(3):619-627. PubMed ID: 29016532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
